Clexio Biosciences Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1
Ending by 2030
Apr 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 16, 2026The maintenance fee for Expandable Gastroretentive Dosage Form (US 11,648,198) comes due Nov 16, 2026. Unpaid by May 17, 2027, it lapses early.
- 1 fee due Feb 22, 2027The maintenance fee for Immediate release abuse-deterrent granulated dosage forms (US 11,730,702) comes due Feb 22, 2027. Unpaid by Aug 23, 2027, it lapses early.
- 1 fee due Mar 10, 2027The maintenance fee for Transdermal Dosage Form (US 10,406,154) comes due Mar 10, 2027. Unpaid by Sep 10, 2027, it lapses early.
- 1 fee due May 26, 2027The maintenance fee for Expandable Gastroretentive Dosage Form (US 10,485,758) comes due May 26, 2027. Unpaid by Nov 26, 2027, it lapses early.
- 1 fee due Jun 19, 2027The maintenance fee for Immediate release abuse-deterrent granulated dosage forms (US 11,844,796) comes due Jun 19, 2027. Unpaid by Dec 20, 2027, it lapses early.
- 1 fee due Jul 9, 2027The maintenance fee for Method of treating major depressive disorder (US 11,865,088) comes due Jul 9, 2027. Unpaid by Jan 10, 2028, it lapses early.
- 2 fees due Aug 20 to 25, 2027 · next Aug 20
- 2 fees due Oct 16 to 23, 2027 · next Oct 16
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,638,651 | Substituted cyclohexanones In force · From the USPTO record | In force | From the USPTO record | |
| US 9,707,224 | Immediate release abuse-deterrent granulated dosage forms In force · From the USPTO record | In force | From the USPTO record | |
| US 9,757,371 | Immediate release abuse-deterrent granulated dosage forms In force · From the USPTO record | In force | From the USPTO record | |
| US 10,568,881 | Immediate release abuse-deterrent granulated dosage forms In force · From the USPTO record | In force | From the USPTO record | |
| US 11,207,318 | Immediate release abuse-deterrent granulated dosage forms In force · From the USPTO record | In force | From the USPTO record | |
| US 11,844,796 | Immediate release abuse-deterrent granulated dosage forms In force · From the USPTO record | In force | From the USPTO record | |
| US 10,485,758 | Expandable Gastroretentive Dosage Form In force · High confidence | In force | High confidence | |
| US 11,648,198 | Expandable Gastroretentive Dosage Form In force · High confidence | In force | High confidence | |
| US 9,827,204 | Immediate release abuse-deterrent granulated dosage forms In force · From the USPTO record | In force | From the USPTO record | |
| US 10,201,505 | Immediate release abuse-deterrent granulated dosage forms In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 37: 5 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 10 abandoned · 19 no status recorded